Immunocore Company Updates | Glassdoor.co.uk

Company Updates

  • Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate Immunocore’s intra-patient dose escalation Phase I IMCgp100 study in metastatic uveal melanoma patients demonstrates a one-year overall survival (OS) rate of 73% (95% confidence interval [46, 88]) and a one-year progression-free-survival (PFS) rate of 62% based on the irRC criteria as of the data cut-off in October 2017. Median OS has not been reached with median follow-up of 12.8 months in this cohort. The overall survival data from this study compare very favourably to studies with other agents, which show one-year OS rates of approximately 25-45%.* For the full press release: http://glassdoor.com/slink.htm?key=vQDGT

Work at Immunocore? Share Your Experiences

Immunocore
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or